InjectAbility Institute, Torrance, California.
J Cosmet Dermatol. 2021 Apr;20(4):1254-1262. doi: 10.1111/jocd.13885. Epub 2020 Dec 28.
The incidence of body dysmorphic disorder in cosmetic dermatology is high. Even though treating patients with this disorder may worsen symptoms and is fraught with potential complications, screening is low, due in part to lack of knowledge of the disorder, as well as inadequate screening tools.
To verify the probability of body dysmorphic disorder in a nonsurgical esthetic setting and determine the effect of a multiphasic screening protocol on mitigating poor outcomes in high-risk patients.
A multiphasic screening protocol for body dysmorphic disorder was distributed to a total of eight esthetic clinics in the United States. Practitioners administered an anonymous, cryptic prescreening form to all new, incoming patients aged ≥ 18 to ≤ 65 years from June 1, 2019, through September 1, 2019, followed by a second, more extensive screening questionnaire. Patients with suspected or subclinical body dysmorphic disorder could be refused treatment.
A total of 734 initial screenings were recorded over 16 weeks. Of these, 4.2% (31/734) proceeded to the secondary screening phase; 29% (9/31) subsequently screened positive for body dysmorphic disorder. Practitioners refused to treat 77.8% (7/9) of positive screenings. Two patients out of seven who tested positive underwent a third screening and were subsequently treated with positive outcomes.
Use of a cryptic screening protocol enables identification of individuals at risk for BDD and encourages open and continuous communication between patient and provider.
美容皮肤科中躯体型态障碍的发病率很高。尽管治疗这类患者可能会使症状恶化,并存在潜在的并发症,但筛查率仍然很低,这部分是由于对这种疾病缺乏了解,以及筛查工具不足。
在非手术美容环境中验证躯体型态障碍的可能性,并确定多相筛查方案对减轻高风险患者不良结局的影响。
一项躯体型态障碍多相筛查方案分发给美国的 8 家美容诊所。从业者于 2019 年 6 月 1 日至 9 月 1 日期间,向所有年龄在 18 岁至 65 岁之间的新入诊患者匿名、隐密地发放了一份预筛查表,然后是第二份更广泛的筛查问卷。疑似或亚临床躯体型态障碍患者可能会被拒绝治疗。
在 16 周的时间内共记录了 734 份初始筛查。其中,4.2%(31/734)进入第二阶段的筛查;29%(9/31)随后筛查出躯体型态障碍阳性。从业者拒绝治疗 77.8%(7/9)的阳性筛查者。7 名阳性测试者中有 2 名接受了第三次筛查,随后得到了积极的治疗结果。
使用隐密筛查方案可以识别出有 BDD 风险的个体,并鼓励患者和提供者之间进行开放和持续的沟通。